JPWO2020180741A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020180741A5 JPWO2020180741A5 JP2021549902A JP2021549902A JPWO2020180741A5 JP WO2020180741 A5 JPWO2020180741 A5 JP WO2020180741A5 JP 2021549902 A JP2021549902 A JP 2021549902A JP 2021549902 A JP2021549902 A JP 2021549902A JP WO2020180741 A5 JPWO2020180741 A5 JP WO2020180741A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- target
- item
- stranded
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 103
- 238000001514 detection method Methods 0.000 claims description 101
- 108091034117 Oligonucleotide Proteins 0.000 claims description 97
- 239000000090 biomarker Substances 0.000 claims description 86
- 206010028980 Neoplasm Diseases 0.000 claims description 74
- 201000011510 cancer Diseases 0.000 claims description 66
- 238000003556 assay Methods 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000003960 Ligases Human genes 0.000 claims description 13
- 108090000364 Ligases Proteins 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 11
- 108010052285 Membrane Proteins Proteins 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000005917 R-SNARE Proteins Human genes 0.000 claims description 10
- 108010005730 R-SNARE Proteins Proteins 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000004077 genetic alteration Effects 0.000 claims description 2
- 231100000118 genetic alteration Toxicity 0.000 claims description 2
- 238000003125 immunofluorescent labeling Methods 0.000 claims description 2
- 238000011528 liquid biopsy Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 230000037439 somatic mutation Effects 0.000 claims description 2
- 238000011477 surgical intervention Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008191 permeabilizing agent Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000010384 proximity ligation assay Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812878P | 2019-03-01 | 2019-03-01 | |
| US62/812,878 | 2019-03-01 | ||
| US202062962722P | 2020-01-17 | 2020-01-17 | |
| US62/962,722 | 2020-01-17 | ||
| PCT/US2020/020529 WO2020180741A1 (en) | 2019-03-01 | 2020-02-28 | Systems, compositions, and methods for target entity detection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521781A JP2022521781A (ja) | 2022-04-12 |
| JPWO2020180741A5 true JPWO2020180741A5 (enExample) | 2023-03-09 |
| JP7344973B2 JP7344973B2 (ja) | 2023-09-14 |
Family
ID=72338354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549902A Active JP7344973B2 (ja) | 2019-03-01 | 2020-02-28 | 標的実体を検出するためのシステム、組成物、及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20220155304A1 (enExample) |
| EP (2) | EP3998349A3 (enExample) |
| JP (1) | JP7344973B2 (enExample) |
| KR (1) | KR102599718B1 (enExample) |
| CN (1) | CN113748217B (enExample) |
| AU (2) | AU2020233286B2 (enExample) |
| CA (1) | CA3129868A1 (enExample) |
| SG (1) | SG11202109423TA (enExample) |
| WO (1) | WO2020180741A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3998349A3 (en) | 2019-03-01 | 2022-08-24 | Mercy Bioanalytics, Inc. | Compositions and methods for target protein detection on exosomes using proximal ligation |
| US20250326855A1 (en) | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| EP4373975A4 (en) * | 2021-07-21 | 2025-04-23 | Mercy Bioanalytics, Inc. | COMPOSITIONS AND METHODS FOR THE DETECTION OF PANCREATIC CANCER |
| WO2023004079A2 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of liver cancer |
| WO2023004087A2 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for cancer detection |
| EP4373962A2 (en) * | 2021-07-21 | 2024-05-29 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of colorectal cancer |
| WO2023004083A2 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of bile duct cancer |
| EP4373860A4 (en) * | 2021-07-21 | 2025-05-21 | Mercy Bioanalytics, Inc. | COMPOSITIONS AND METHODS FOR THE DETECTION OF PROSTATE CANCER |
| US20250043357A1 (en) * | 2021-07-21 | 2025-02-06 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of esophageal cancer |
| CA3227119A1 (en) * | 2021-07-21 | 2023-01-26 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of breast cancer |
| EP4380604A1 (en) | 2021-08-05 | 2024-06-12 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｌａｍｐ１抗体およびその使用 |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| WO2024112615A1 (en) * | 2022-11-23 | 2024-05-30 | Range Biotechnologies, Inc. | Compositions and methods for detection of protein analytes |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795714A (en) | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
| CA2118759C (en) | 1993-04-21 | 2004-06-22 | William Jeffrey Allard | Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood |
| US20020025519A1 (en) * | 1999-06-17 | 2002-02-28 | David J. Wright | Methods and oligonucleotides for detecting nucleic acid sequence variations |
| US7306904B2 (en) | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| EP1451356A1 (en) | 2001-11-23 | 2004-09-01 | Simon Fredriksson | Method and kit for proximity probing with multivalent proximity probes |
| CN101410530B (zh) | 2003-04-18 | 2013-03-27 | 贝克顿·迪金森公司 | 免疫-扩增 |
| PT1633888E (pt) * | 2003-06-17 | 2009-04-22 | Keygene Nv | Meios e método para a detecção de sequências de nucleótidos alvo utilizando ensaios de ligação com pares de sondas de oligonucleótido melhoradas |
| US7914987B2 (en) | 2004-06-14 | 2011-03-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in analyte detection using proximity probes |
| GB0605584D0 (en) | 2006-03-20 | 2006-04-26 | Olink Ab | Method for analyte detection using proximity probes |
| US8758991B2 (en) | 2006-04-26 | 2014-06-24 | University Of Louisville Research Foundation, Inc. | Isolation of membrane vesicles from biological fluids and methods of using same |
| EP2227556B1 (en) | 2007-11-19 | 2014-08-27 | Celera Corporation | Lung cancer markers and uses thereof |
| US8481698B2 (en) | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
| GB201004292D0 (en) | 2010-03-15 | 2010-04-28 | Olink Ab | Assay for localised detection of analytes |
| US10669569B2 (en) | 2010-10-15 | 2020-06-02 | Navinci Diagnostics Ab | Dynamic range methods |
| EP2638057B1 (en) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| EP3569607A1 (en) | 2011-05-11 | 2019-11-20 | Exosome Diagnostics, Inc. | Nucleic acid extraction from heterogeneous biological materials |
| KR102085242B1 (ko) * | 2011-05-17 | 2020-03-05 | 디엑스테리티 다이아그노스틱스 인코포레이티드 | 표적 핵산 검출을 위한 방법 및 조성물 |
| GB201108678D0 (en) | 2011-05-24 | 2011-07-06 | Olink Ab | Multiplexed proximity ligation assay |
| US10174361B2 (en) | 2011-11-10 | 2019-01-08 | Exosome Diagnostics, Inc. | Cerebrospinal fluid assay |
| US9029086B2 (en) | 2012-01-26 | 2015-05-12 | Masood Kamali Moghaddam | Detection of single and multimodal analytes |
| EP2875158A4 (en) | 2012-07-18 | 2016-03-23 | Exosome Diagnostics Inc | USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN |
| CN105025878A (zh) | 2012-10-03 | 2015-11-04 | 外来体诊断公司 | 微泡在医学疾病和病况的诊断、预后和治疗中的用途 |
| WO2014076214A1 (en) | 2012-11-14 | 2014-05-22 | Olink Ab | Rca reporter probes and their use in detecting nucleic acid molecules |
| US10174366B2 (en) | 2012-11-14 | 2019-01-08 | Olink Bioscience Ab | Localised RCA-based amplification method |
| US9086412B2 (en) | 2012-12-31 | 2015-07-21 | University Of Louisville Research Foundation, Inc. | Extracellular vesicle-associated protein markers of cancer |
| BR112015016136A2 (pt) | 2013-01-03 | 2017-07-11 | Exosome Diagnostics Inc | métodos para isolar microvesículas |
| US10301681B2 (en) | 2013-08-06 | 2019-05-28 | Exosome Diagnostics, Inc. | Methods of treating a subject with a high gleason score prostate cancer |
| US20160319361A1 (en) * | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
| WO2015047186A1 (en) | 2013-09-30 | 2015-04-02 | Di Wu | Methods to profile molecular complexes by using proximity bar-coding |
| GB201401885D0 (en) | 2014-02-04 | 2014-03-19 | Olink Ab | Proximity assay with detection based on hybridisation chain reaction (HCR) |
| US20170014450A1 (en) | 2014-02-28 | 2017-01-19 | Exosome Sciences, Inc. | Brain specific exosome based diagnostics and extracorporeal therapies |
| EP3143401A4 (en) * | 2014-05-15 | 2017-10-11 | Meso Scale Technologies, LLC | Improved assay methods |
| CA3213538A1 (en) * | 2014-06-06 | 2015-12-10 | Cornell University | Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions |
| WO2015193427A1 (en) | 2014-06-19 | 2015-12-23 | Olink Ab | Determination and analysis of biomarkers in clinical samples |
| WO2016093838A1 (en) * | 2014-12-11 | 2016-06-16 | New England Biolabs, Inc. | Enrichment of target sequences |
| US11175286B2 (en) * | 2015-01-09 | 2021-11-16 | Spot Biosystems Ltd. | Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles |
| WO2016145128A1 (en) * | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| CA2999283A1 (en) * | 2015-09-22 | 2017-03-30 | Trustees Of Boston University | Multiplexed phenotyping of nanovesicles |
| GB201518655D0 (en) | 2015-10-21 | 2015-12-02 | Olink Ab | Method for generating proximity probes |
| US10526665B2 (en) * | 2016-03-04 | 2020-01-07 | University Of Notre Dame Du Lac | Exosomal biomarkers diagnostic of tuberculosis |
| FI3464628T3 (fi) * | 2016-06-06 | 2024-05-03 | Redvault Biosciences Lp | Kohdereportterikonstruktit ja niiden käyttö |
| AU2017366813B2 (en) * | 2016-11-30 | 2023-04-20 | Exosome Diagnostics, Inc. | Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients |
| WO2018119455A1 (en) | 2016-12-23 | 2018-06-28 | Exosome Diagnostics, Inc. | Biofluid analysis and quantitation systems and methods |
| EP3652315A4 (en) * | 2017-07-12 | 2021-09-01 | Exosome Diagnostics, Inc. | METHODS FOR ISOLATION AND ENRICHMENT OF EXTRACELLULAR VESICLE POPULATIONS DERIVED FROM BIOFLUIDS, AND ASSOCIATED METHODS OF USE |
| EP3655531B1 (en) | 2017-07-18 | 2024-09-04 | Exosome Diagnostics, Inc. | Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme |
| WO2019022542A2 (ko) | 2017-07-26 | 2019-01-31 | ㈜로제타엑소좀 | 양이온을 이용한 세포밖 소포체의 분리 방법 |
| US11904259B2 (en) | 2017-07-26 | 2024-02-20 | Rosetta Exosome | Method for isolating extracellular vesicles using cations |
| WO2019066501A1 (ko) | 2017-09-27 | 2019-04-04 | ㈜로제타엑소좀 | 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도 |
| WO2019103548A2 (ko) | 2017-11-24 | 2019-05-31 | ㈜로제타엑소좀 | 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법 |
| US20200362334A1 (en) * | 2017-12-07 | 2020-11-19 | The Broad Institute, Inc. | High-throughput methods for identifying gene interactions and networks |
| WO2019222708A2 (en) * | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| US12378608B2 (en) | 2018-06-06 | 2025-08-05 | Exosome Diagnostics, Inc. | Methods for developing urine biomarkers and for detecting bladder cancer |
| WO2019238944A1 (en) | 2018-06-15 | 2019-12-19 | Olink Proteomics Ab | Biomarker panel for ovarian cancer |
| WO2020086751A1 (en) * | 2018-10-23 | 2020-04-30 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| WO2020106853A1 (en) | 2018-11-20 | 2020-05-28 | Exosome Diagnostics, Inc. | Compositions and methods for internal controls of microvesicle isolations |
| EP3998349A3 (en) | 2019-03-01 | 2022-08-24 | Mercy Bioanalytics, Inc. | Compositions and methods for target protein detection on exosomes using proximal ligation |
| JP2023510911A (ja) * | 2020-01-17 | 2023-03-15 | マーシー バイオアナリティクス， インコーポレイテッド | 卵巣癌を検出するための組成物及び方法 |
-
2020
- 2020-02-28 EP EP21201011.0A patent/EP3998349A3/en active Pending
- 2020-02-28 US US17/435,697 patent/US20220155304A1/en active Pending
- 2020-02-28 CN CN202080017641.1A patent/CN113748217B/zh active Active
- 2020-02-28 KR KR1020217031580A patent/KR102599718B1/ko active Active
- 2020-02-28 SG SG11202109423TA patent/SG11202109423TA/en unknown
- 2020-02-28 US US16/805,637 patent/US11085089B2/en active Active
- 2020-02-28 AU AU2020233286A patent/AU2020233286B2/en active Active
- 2020-02-28 EP EP20766432.7A patent/EP3931351B1/en active Active
- 2020-02-28 CA CA3129868A patent/CA3129868A1/en active Pending
- 2020-02-28 WO PCT/US2020/020529 patent/WO2020180741A1/en not_active Ceased
- 2020-02-28 JP JP2021549902A patent/JP7344973B2/ja active Active
-
2021
- 2021-03-17 US US17/204,773 patent/US20210214806A1/en active Pending
-
2022
- 2022-10-03 AU AU2022241629A patent/AU2022241629B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2492498T3 (es) | Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto | |
| US20080206756A1 (en) | Biomarker panel for colorectal cancer | |
| US11827938B2 (en) | Methods of prostate cancer prognosis | |
| CN104620109A (zh) | 膀胱癌检测组合物、试剂盒及相关的方法 | |
| EP1339872A2 (en) | Genetic markers for tumors | |
| WO2017210372A1 (en) | Molecular tagging methods and sequencing libraries | |
| JP2023533970A (ja) | 肺癌を検出するための組成物及び方法 | |
| JPWO2020180741A5 (enExample) | ||
| US20230368915A1 (en) | Metastasis predictor | |
| CN105431737A (zh) | 用于预测局部晚期胃癌预后的系统 | |
| JP2009515553A (ja) | 癌の予知および予後と、癌治療のモニタリング | |
| CN113493829B (zh) | 生物标志物在肺动脉高压诊疗中的应用 | |
| JP2010518868A (ja) | 前立腺癌の生存及び再発 | |
| WO2006062118A1 (ja) | 甲状腺乳頭癌の予後を予測するための新規のマーカー | |
| Macerola et al. | NanoString in the screening of genetic abnormalities associated with thyroid cancer | |
| CN113502326B (zh) | 基于生物标志物的肺动脉高压的诊断产品及其应用 | |
| CN108913772B (zh) | 基于捕获测序的bMSI检测技术 | |
| WO2018186687A1 (ko) | 생물학적 시료의 핵산 품질을 결정하는 방법 | |
| WO2020194057A1 (en) | Biomarkers for disease detection | |
| CN109642257B (zh) | 药物疗法对癌的效果的预测方法 | |
| Galbraith et al. | Detection of Gene Fusions and Rearrangements in Formalin-Fixed, Paraffin-Embedded Solid Tumor Specimens Using High-Throughput Chromosome Conformation Capture | |
| US20230175071A1 (en) | Liquid biopsy platform in plasma and saliva | |
| JP2024519082A (ja) | 肝細胞がんのｄｎａメチル化バイオマーカー | |
| US20230133776A1 (en) | Methods for diagnosing cancer | |
| JP2007532142A (ja) | 乳がん遺伝子発現バイオマーカー |